Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Eastern Cooperative Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 2012-01-01

Employees: 51

Market Cap: -

Website: https://ecog-acrin.org

Clinical Trials

Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma

Not Applicable

Not yet recruiting

Conditions: Melanoma

Interventions: Drug: Sulforaphane (broccoli sprout extract)
Drug: Placebo
Device: Derma-AI

First Posted Date: 2025-06-27

Last Posted Date: 2025-06-27

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 120

Registration Number: NCT07040280

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol

Not yet recruiting

Conditions: Breast Cancer

First Posted Date: 2025-01-22

Last Posted Date: 2025-05-30

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 600

Registration Number: NCT06786585

The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials

Not Applicable

Recruiting

Conditions: Cancer

First Posted Date: 2025-01-03

Last Posted Date: 2025-06-25

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 500

Registration Number: NCT06756607

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Phase 3

Not yet recruiting

Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative
Follicular Helper T-Cell Lymphoma
Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
Peripheral T-Cell Lymphoma, Not Otherwise Specified

Interventions: Other: Best Practice
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Drug: High Dose Chemotherapy
Procedure: Leukapheresis
Drug: Stem Cell Mobilization Therapy

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-09

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 294

Registration Number: NCT06724237

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment

Phase 2

Not yet recruiting

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Cytarabine
Drug: CPX-351
Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2022-11-28

Last Posted Date: 2024-07-03

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 184

Registration Number: NCT05628623

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Phase 2

Recruiting

Conditions: T-cell Acute Lymphoblastic Leukemia

Interventions: Drug: Daratumumab / Hyaluronidase Injection

First Posted Date: 2022-03-21

Last Posted Date: 2024-12-12

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 20

Registration Number: NCT05289687

Locations: 🇺🇸
Northwestern, Chicago, Illinois, United States

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Not Applicable

Recruiting

Conditions: Cervical Cancer, NOS
Miscellaneous Neoplasm, NOS
Bone Cancer, NOS
Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS
Melanoma
Breast Cancer, NOS
Testicular Nonseminomatous Germ Cell Tumor, NOS
CNS Primary Tumor, NOS
Lymphoma, NOS
Thyroid Cancer, NOS

Interventions: Other: Questionnaires

First Posted Date: 2021-11-04

Last Posted Date: 2024-10-30

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 400

Registration Number: NCT05108298

Locations: 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

and more 341 locations

COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation

Terminated

Conditions: Breast Cancer, NOS

Interventions: Other: Questionnaire

First Posted Date: 2021-10-13

Last Posted Date: 2025-03-25

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 14

Registration Number: NCT05076266

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia

Phase 3

Completed

Conditions: Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia

Interventions: Drug: Placebo
Drug: GM-CSF priming

First Posted Date: 2020-06-24

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 362

Registration Number: NCT04446052

Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer

Phase 3

Completed

Conditions: Stage I-II Head and Neck Cancer

Interventions: Drug: 13-cis retinoic acid
Other: Placebo

First Posted Date: 2017-12-12

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 189

Registration Number: NCT03370367

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy